For what concerns the PD1/PD-L1 checkpoint, the anti-PD1 agents, among which nivolumab and pembrolizumab, and the anti-PD-L1 drugs, such as atezolizumab, avelumab and durvalumab, paved the way for a radical change in the therapeutic algorithm of several tumors, like melanoma, NSCLC and mRCC, as well as urothelial carcinoma, Merkel Cell Carcinoma and Hodgkin lymphoma. Here, CD274 is linked to urothelial carcinoma.